Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

被引：0
|
作者：
Sayani, Shermin [1 ]
Iqbal, Omer [1 ]
Hoppensteadt, Debra [1 ]
Fareed, Jawed [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 48 条
  • [31] Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry
    Gous, Tracey
    Couchman, Lewis
    Patel, Jignesh P.
    Paradzai, Chitongo
    Arya, Roopen
    Flanagan, Robert J.
    THERAPEUTIC DRUG MONITORING, 2014, 36 (05) : 597 - 605
  • [32] Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland
    Coumau, Claire
    Gaspar, Frederic
    Terrier, Jean
    Schulthess-Lisibach, Angela
    Lutters, Monika
    Le Pogam, Marie-Annick
    Csajka, Chantal
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [33] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Banerjee, Amitava
    Lane, Deirdre A.
    Torp-Pedersen, Christian
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 584 - 589
  • [34] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
    Cohen, A. T.
    Hamilton, M.
    Mitchell, S. A.
    Phatak, H.
    Liu, X.
    Bird, A.
    Tushabe, D.
    Batson, S.
    PLOS ONE, 2015, 10 (12):
  • [35] Drug-drug interactions between direct oral anticoagulants and anticancer drugs: A single center bleeding complications in the Netherlands
    Appelman, E. M.
    Martens, E. S. L.
    Burger, D. M.
    van Gelder, T.
    van der Hulle, T.
    van Rein, N.
    Klok, F. A.
    THROMBOSIS RESEARCH, 2025, 245
  • [36] Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
    Schmitz, E. M. H.
    Boonen, K.
    van den Heuvel, D. J. A.
    van Dongen, J. L. J.
    Schellings, M. W. M.
    Emmen, J. M. A.
    van der Graaf, F.
    Brunsveld, L.
    van de Kerkhof, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (10) : 1636 - 1646
  • [37] Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'
    Kakkos, S. K.
    Kirkilesis, G. I.
    Tsolakis, I. A.
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2015, 50 (01) : 127 - 127
  • [38] Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Lip, G. Y. H.
    Keshishian, A.
    Kamble, S.
    Pan, X.
    Burns, L.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 501
  • [39] Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    Squibb, Bristol-Myers
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [40] Drug Interactions with the Newer Antiepileptic Drugs (AEDs)-Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders
    Patsalos, Philip N.
    CLINICAL PHARMACOKINETICS, 2013, 52 (12) : 1045 - 1061
12345